Title The incidence, genetic characteristics, and prognosis of leukemia with concurrent pathogenic fusion genes: a series of 25 cases from a large cohort of leukemia patients
Authors Chen, Xue
Wang, Fang
Wang, Tong
Zhang, Yang
Ma, Xiaoli
Yuan, Lili
Teng, Wen
Guo, Lei
Liu, Mingyue
Liu, Ming
Chen, Jiaqi
Nie, Daijing
Zhang, Yu
Zhou, Xiaosu
Wang, Mangju
Chen, Kylan N.
Zhu, Ping
Liu, Hongxing
Affiliation Hebei Yanda Lu Daopei Hosp, Divison Pathol & Lab Med, Langfang, Peoples R China
Peking Univ First Hosp, Dept Hematol, Beijing, Beijing, Peoples R China
Beijing Lu Daopei Inst Hematol, Beijing, Beijing, Peoples R China
Beijing Lu Daopei Hosp, Divison Pathol & Lab Med, Beijing, Beijing, Peoples R China
Keywords WORLD-HEALTH-ORGANIZATION
MYELOID-LEUKEMIA
2016 REVISION
CLASSIFICATION
NEOPLASMS
ACTIVATION
BCR-ABL1
PROTEIN
Issue Date Feb-2020
Publisher CANCER GENE THERAPY
Abstract Recurrent fusion genes (FGs) with clinical significances in leukemias are mainly mutually exclusive, and the coexistence of different FGs has been rarely reported. In this study, we retrospectively analyzed the incidence, genetic characteristics, and prognosis of leukemias with concurrent pathogenic FGs, which commonly reported in hematological malignancies in 8226 leukemia patients. A total of 25 patients with coexistence of double FGs were identified, accounting for 0.30% of all cases enrolled. More than half of the cases (14/25, 56%) were diagnosed as chronic myeloid leukemia in accelerated or blast phase, another six and five cases were acute myeloid leukemia and acute lymphocytic leukemia, respectively. Most cases (20/25, 80%) carried constitutively activated tyrosine kinases FGs (BCR-ABL1 or ETV6-PDGFRB) and transcription factors associated FGs simultaneously. Of the 11 patients with contemporaneous karyotype, 5 (45%) showed visible chromosomal abnormalities corresponding to both FGs. The concurrency of FGs was often associated with disease progressions. The prognosis was pessimistic for patients with concurrent FGs, even with the combination of targeted therapy and chemotherapy. Performing allogeneic hematopoietic stem cell transplantation as soon as possible after complete remission can ameliorate the dismal prognosis.
URI http://hdl.handle.net/20.500.11897/586181
ISSN 0929-1903
DOI 10.1038/s41417-019-0147-1
Indexed SCI(E)
Appears in Collections: 第一医院

Files in This Work
There are no files associated with this item.

Web of Science®


0

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.